These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 20738033

  • 1. Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
    Prescrire Int; 2010 Jun; 19(107):109-12. PubMed ID: 20738033
    [Abstract] [Full Text] [Related]

  • 2. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Jun; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 3. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 4. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 5. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 6. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.
    J Med Econ; 2012 Nov; 15(4):746-57. PubMed ID: 22443463
    [Abstract] [Full Text] [Related]

  • 7. Liraglutide: from clinical trials to clinical practice.
    Gough SC.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [Abstract] [Full Text] [Related]

  • 8. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L, Montanya E.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [Abstract] [Full Text] [Related]

  • 9. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.
    J Med Econ; 2012 Apr; 15(6):1039-50. PubMed ID: 22533526
    [Abstract] [Full Text] [Related]

  • 10. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C, Batel-Marques F, Macedo AF.
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [Abstract] [Full Text] [Related]

  • 11. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG.
    MMW Fortschr Med; 2007 Jun 21; 149(25-26):41-3. PubMed ID: 17713050
    [Abstract] [Full Text] [Related]

  • 12. Exenatide: new drug. Type 2 diabetes for some overweight patients.
    Prescrire Int; 2007 Dec 21; 16(92):228-31. PubMed ID: 18087791
    [Abstract] [Full Text] [Related]

  • 13. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV, Rodgers PT, Scates AC.
    Ann Pharmacother; 2005 Jan 21; 39(1):110-8. PubMed ID: 15562141
    [Abstract] [Full Text] [Related]

  • 14. Acute pancreatitis associated with liraglutide.
    Lee PH, Stockton MD, Franks AS.
    Ann Pharmacother; 2011 Apr 21; 45(4):e22. PubMed ID: 21487080
    [Abstract] [Full Text] [Related]

  • 15. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M.
    J Clin Endocrinol Metab; 2011 Jun 21; 96(6):1695-702. PubMed ID: 21450987
    [Abstract] [Full Text] [Related]

  • 16. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May 21; 48(5):50-3. PubMed ID: 20447980
    [Abstract] [Full Text] [Related]

  • 17. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
    Madsbad S.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug 21; 23(4):463-77. PubMed ID: 19748064
    [Abstract] [Full Text] [Related]

  • 18. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B.
    Diabetes Obes Metab; 2013 Jan 21; 15(1):42-54. PubMed ID: 22862847
    [Abstract] [Full Text] [Related]

  • 19. The design of the liraglutide clinical trial programme.
    Nauck MA.
    Diabetes Obes Metab; 2012 Apr 21; 14 Suppl 2():4-12. PubMed ID: 22405264
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E, Jonker DM, Jacobsen LV, Ingwersen SH.
    J Clin Pharmacol; 2010 Aug 21; 50(8):886-94. PubMed ID: 20133507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.